CA2586174A1 - Methods of preparing indazole compounds - Google Patents
Methods of preparing indazole compounds Download PDFInfo
- Publication number
- CA2586174A1 CA2586174A1 CA002586174A CA2586174A CA2586174A1 CA 2586174 A1 CA2586174 A1 CA 2586174A1 CA 002586174 A CA002586174 A CA 002586174A CA 2586174 A CA2586174 A CA 2586174A CA 2586174 A1 CA2586174 A1 CA 2586174A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- reaction
- compounds
- catalyst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *c1c(C(N*)=O)c(Sc2ccc3c(I)n[n]c3c2)c(*)cc1 Chemical compound *c1c(C(N*)=O)c(Sc2ccc3c(I)n[n]c3c2)c(*)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62463504P | 2004-11-02 | 2004-11-02 | |
| US60/624,635 | 2004-11-02 | ||
| US71707105P | 2005-09-14 | 2005-09-14 | |
| US60/717,071 | 2005-09-14 | ||
| PCT/IB2005/003297 WO2006048744A1 (en) | 2004-11-02 | 2005-10-21 | Methods of preparing indazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2586174A1 true CA2586174A1 (en) | 2006-05-11 |
Family
ID=35744929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002586174A Abandoned CA2586174A1 (en) | 2004-11-02 | 2005-10-21 | Methods of preparing indazole compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7232910B2 (enExample) |
| EP (1) | EP1809621A1 (enExample) |
| JP (1) | JP2008518900A (enExample) |
| KR (1) | KR20070058690A (enExample) |
| AR (1) | AR051754A1 (enExample) |
| AU (1) | AU2005300310A1 (enExample) |
| BR (1) | BRPI0518203A2 (enExample) |
| CA (1) | CA2586174A1 (enExample) |
| IL (1) | IL182693A0 (enExample) |
| MX (1) | MX2007005291A (enExample) |
| NO (1) | NO20071619L (enExample) |
| RU (1) | RU2007116107A (enExample) |
| TW (1) | TWI294421B (enExample) |
| WO (1) | WO2006048744A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679356A (zh) | 2007-04-05 | 2010-03-24 | 辉瑞产品公司 | 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型 |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| EP2163544A1 (en) * | 2008-09-16 | 2010-03-17 | Pfizer, Inc. | Methods of preparing indazole compounds |
| CA2949515C (en) | 2009-01-08 | 2018-10-23 | Axel Becker | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
| TW201531309A (zh) | 2011-09-30 | 2015-08-16 | Pfizer | Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物 |
| JP2014533262A (ja) | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド |
| US9899120B2 (en) | 2012-11-02 | 2018-02-20 | Nanotek Instruments, Inc. | Graphene oxide-coated graphitic foil and processes for producing same |
| US10087073B2 (en) | 2013-02-14 | 2018-10-02 | Nanotek Instruments, Inc. | Nano graphene platelet-reinforced composite heat sinks and process for producing same |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| HUE046727T2 (hu) * | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| RU2667486C2 (ru) * | 2014-03-31 | 2018-09-20 | Сэндзю Фармацевтикал Ко., Лтд. | Производное алкинилиндазола и его применение |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| WO2016108106A1 (en) * | 2014-12-29 | 2016-07-07 | Shilpa Medicare Limited | An improved process for preparation of axitinib |
| KR20170132171A (ko) | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 ｐｄ１ ／ ｐｄｌ１ 저해제 |
| US9580406B2 (en) | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| ES2982700T3 (es) | 2019-04-18 | 2024-10-17 | Synthon Bv | Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib |
| IL315262A (en) | 2022-03-03 | 2024-10-01 | Pfizer | Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| KR101099281B1 (ko) * | 2003-03-03 | 2011-12-26 | 어레이 바이오파마 인크. | ｐ38 억제제 및 그의 사용 방법 |
| KR20050119671A (ko) * | 2003-04-03 | 2005-12-21 | 화이자 인코포레이티드 | Ａｇ013736을 포함하는 제형 |
| US20080274192A1 (en) | 2005-05-19 | 2008-11-06 | Pfizer Inc. | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor |
-
2005
- 2005-10-21 JP JP2007538537A patent/JP2008518900A/ja not_active Withdrawn
- 2005-10-21 KR KR1020077009848A patent/KR20070058690A/ko not_active Ceased
- 2005-10-21 BR BRPI0518203-4A patent/BRPI0518203A2/pt not_active IP Right Cessation
- 2005-10-21 RU RU2007116107/04A patent/RU2007116107A/ru not_active Application Discontinuation
- 2005-10-21 MX MX2007005291A patent/MX2007005291A/es not_active Application Discontinuation
- 2005-10-21 EP EP05804650A patent/EP1809621A1/en not_active Withdrawn
- 2005-10-21 AU AU2005300310A patent/AU2005300310A1/en not_active Abandoned
- 2005-10-21 CA CA002586174A patent/CA2586174A1/en not_active Abandoned
- 2005-10-21 WO PCT/IB2005/003297 patent/WO2006048744A1/en not_active Ceased
- 2005-10-28 TW TW094137922A patent/TWI294421B/zh active
- 2005-10-31 US US11/264,440 patent/US7232910B2/en not_active Expired - Fee Related
- 2005-11-01 AR ARP050104568A patent/AR051754A1/es unknown
-
2007
- 2007-03-28 NO NO20071619A patent/NO20071619L/no not_active Application Discontinuation
- 2007-04-19 IL IL182693A patent/IL182693A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006048744A1 (en) | 2006-05-11 |
| BRPI0518203A2 (pt) | 2009-03-10 |
| TWI294421B (en) | 2008-03-11 |
| KR20070058690A (ko) | 2007-06-08 |
| RU2007116107A (ru) | 2008-11-10 |
| EP1809621A1 (en) | 2007-07-25 |
| US7232910B2 (en) | 2007-06-19 |
| TW200621721A (en) | 2006-07-01 |
| AR051754A1 (es) | 2007-02-07 |
| IL182693A0 (en) | 2007-09-20 |
| US20060094881A1 (en) | 2006-05-04 |
| MX2007005291A (es) | 2007-07-19 |
| NO20071619L (no) | 2007-04-25 |
| JP2008518900A (ja) | 2008-06-05 |
| AU2005300310A1 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7232910B2 (en) | Methods of preparing indazole compounds | |
| US20070203196A1 (en) | Methods of preparing indazole compounds | |
| TWI658042B (zh) | 雜環化合物的合成 | |
| TWI603970B (zh) | 雜環化合物之合成 | |
| AU2005300311A1 (en) | Methods for preparing indazole compounds | |
| CA2627839A1 (en) | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | |
| AU2014337064A1 (en) | Bromodomain inhibitors | |
| CN102015720A (zh) | 神经元烟碱性受体的选择性配体及其应用 | |
| CN101094836A (zh) | 制备吲唑化合物的方法 | |
| CA2819102A1 (en) | Kat ii inhibitors | |
| RU2669701C2 (ru) | Производные пиперидина в качестве антагонистов рецептора орексина | |
| EP3752250B1 (en) | P300/cbp hat inhibitors | |
| TW202246282A (zh) | Ｍｋ２抑制劑、其合成及其中間體 | |
| CN107176955A (zh) | 一种巴瑞替尼的制备方法 | |
| EP3412666A1 (en) | Process and intermediates for the preparation of bcl-2 inhibitors including venetoclax through reductive amination | |
| TWI331602B (en) | A coupling process for preparing quinolone intermediates | |
| JP2026500291A (ja) | Ｔｐ５３－ｙ２２０ｃ変異体をターゲティングするための化合物及び組成物 | |
| TWI468405B (zh) | １Ｈ－吡唑并〔４，３－ｃ〕異喹啉衍生物、其製備及其於醫療上之應用 | |
| EP2163544A1 (en) | Methods of preparing indazole compounds | |
| WO2016020711A1 (en) | Process for the preparation of apixaban | |
| AU2011206717A1 (en) | Methods for the preparation of indazole-3-carboxyclic acid and N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt | |
| TW202328074A (zh) | 製備取代之吡唑并嘧啶之方法 | |
| HK40114080A (en) | Methods of preparing substituted pyrazolopyrimidines | |
| US20050090668A1 (en) | Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds | |
| CN121620512A (zh) | 奥布替尼的制备方法及其中间体化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |